In multiple myeloma cells, overexpression of SPRY2 decreased vascular endothelial growth factor secretion, increased ERK inhibitor sensitivity in vitro, and inhibited tumor formation in vivo.25 Here, VEGFA is linked to plasma cell myeloma.